Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$204.78 +1.6%	$190.74	$163.81 ▼ $218.66	$355.91B	0.5	4.95 million shs	4.63 million shs
AVNR (AVNR)		$0.00	$0.00 ▼ $0.00	N/A	N/A	N/A	N/A
JNJ Johnson & Johnson	$174.96 +0.3%	$160.85	$140.68 ▼ $175.72	$420.06B	0.41	8.58 million shs	8.24 million shs
LLY Eli Lilly and Company	$685.27 +3.8%	$765.92	$623.78 ▼ $972.53	$625.13B	0.44	6.13 million shs	8.34 million shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	+1.70%	+3.02%	+9.77%	+11.28%	+6.13%
JNJ Johnson & Johnson	+0.39%	+2.07%	+12.60%	+15.59%	+10.41%
LLY Eli Lilly and Company	+3.76%	+7.05%	-11.32%	-9.50%	-26.34%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABBV AbbVie	4.7389 of 5 stars	2.5	4.0	3.3	3.9	4.0	2.5	1.3
AVNR (AVNR)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
JNJ Johnson & Johnson	4.8501 of 5 stars	2.3	5.0	4.2	3.9	3.6	1.7	1.9
LLY Eli Lilly and Company	4.9993 of 5 stars	4.3	5.0	3.3	4.0	3.7	3.3	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABBV AbbVie	2.93	Moderate Buy	$214.95	4.97% Upside
AVNR (AVNR)	0.00	N/A	N/A	N/A
JNJ Johnson & Johnson	2.65	Moderate Buy	$174.50	-0.26% Downside
LLY Eli Lilly and Company	2.65	Moderate Buy	$964.88	40.80% Upside

Current Analyst Ratings Breakdown

Latest AVNR, LLY, JNJ, and ABBV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	LLY Eli Lilly and Company	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Overweight ➝ Overweight	$825.00
8/13/2025	LLY Eli Lilly and Company	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$942.00 ➝ $875.00
8/12/2025	ABBV AbbVie	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$231.00
8/11/2025	LLY Eli Lilly and Company	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$1,010.00 ➝ $900.00
8/8/2025	LLY Eli Lilly and Company	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$1,050.00 ➝ $895.00
8/7/2025	ABBV AbbVie	Daiwa America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/7/2025	ABBV AbbVie	Daiwa Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Outperform	$214.00
8/7/2025	LLY Eli Lilly and Company	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/7/2025	LLY Eli Lilly and Company	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$715.00
8/1/2025	ABBV AbbVie	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$250.00 ➝ $255.00
8/1/2025	ABBV AbbVie	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$216.00 ➝ $227.00

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABBV AbbVie	$56.33B	6.42	$15.18 per share	13.49	($0.08) per share	-2,559.69
AVNR (AVNR)	N/A	N/A	N/A	N/A	N/A	N/A
JNJ Johnson & Johnson	$88.82B	4.74	$13.16 per share	13.29	$32.58 per share	5.37
LLY Eli Lilly and Company	$45.04B	14.40	$14.77 per share	46.40	$19.39 per share	35.34

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABBV AbbVie	$4.28B	$2.10	97.51	14.65	1.29	6.45%	699.66%	13.64%	10/29/2025 (Estimated)
AVNR (AVNR)	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
JNJ Johnson & Johnson	$14.07B	$9.35	18.71	15.81	2.22	25.00%	32.49%	13.00%	10/21/2025 (Estimated)
LLY Eli Lilly and Company	$10.59B	$15.30	44.79	22.02	0.93	25.91%	92.72%	16.89%	10/29/2025 (Estimated)

Latest AVNR, LLY, JNJ, and ABBV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	LLY Eli Lilly and Company	$5.59	$6.31	+$0.72	$6.29	$14.40 billion	$15.56 billion
7/31/2025	Q2 2025	ABBV AbbVie	$3.24	$2.97	-$0.27	$0.52	$14.93 billion	$15.42 billion
7/16/2025	Q2 2025	JNJ Johnson & Johnson	$2.68	$2.77	+$0.09	$2.29	$22.85 billion	$23.74 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABBV AbbVie	$6.56	3.20%	N/A	312.38%	53 Years
AVNR (AVNR)	N/A	N/A	N/A	N/A	N/A
JNJ Johnson & Johnson	$5.20	2.97%	N/A	55.61%	64 Years
LLY Eli Lilly and Company	$6.00	0.88%	N/A	39.22%	11 Years

Latest AVNR, LLY, JNJ, and ABBV Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/23/2025	LLY Eli Lilly and Company	quarterly	$1.50	0.78%	8/15/2025	8/15/2025	9/10/2025
7/16/2025	JNJ Johnson & Johnson	quarterly	$1.30	3.35%	8/26/2025	8/26/2025	9/9/2025
6/20/2025	ABBV AbbVie	quarterly	$1.64	3.54%	7/15/2025	7/15/2025	8/15/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABBV AbbVie	44.14	0.74	0.61
AVNR (AVNR)	N/A	N/A	N/A
JNJ Johnson & Johnson	0.50	1.01	0.76
LLY Eli Lilly and Company	1.86	1.28	1.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABBV AbbVie	70.23%
AVNR (AVNR)	N/A
JNJ Johnson & Johnson	69.55%
LLY Eli Lilly and Company	82.53%

Insider Ownership

Company	Insider Ownership
ABBV AbbVie	0.25%
AVNR (AVNR)	N/A
JNJ Johnson & Johnson	0.16%
LLY Eli Lilly and Company	0.13%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABBV AbbVie	55,000	1.77 billion	1.76 billion	Optionable
AVNR (AVNR)	N/A	N/A	N/A	Not Optionable
JNJ Johnson & Johnson	138,100	2.41 billion	2.40 billion	Optionable
LLY Eli Lilly and Company	47,000	946.46 million	945.23 million	Optionable

AVNR, LLY, JNJ, and ABBV Headlines

Recent News About These Companies

Eli Lilly signs $1.3 billion deal with Superluminal to use AI to make obesity medicines

3 hours ago | fastcompany.comF

Eli Lilly to hike UK price of weight-loss drug Mounjaro

3 hours ago | proactiveinvestors.co.uk

Eli Lilly Strikes $1.3 Billion Deal With Superluminal To Develop AI-Driven Obesity Drugs

3 hours ago | benzinga.com

Eli Lilly and Company (NYSE:LLY) Shares Up 2.7% After Insider Buying Activity

4 hours ago | americanbankingnews.com

Eli Lilly raises price of diabetes drug Mounjaro in UK ahead of Trump deadline

August 14 at 7:02 PM | youtube.comY

Guidance Watch: 2 Companies Bullishly Raising Forecasts

August 14 at 6:21 PM | zacks.com

Oracle, Eli Lilly, Terawulf: Trending Tickers

August 14 at 5:53 PM | finance.yahoo.com

Eli Lilly and Company (LLY): “Wall Street Was Really Wrong,” Says Jim Cramer

August 14 at 2:27 PM | insidermonkey.com

Eli Lilly said it is in talks to raise drug prices in Europe, starting with weight-loss drug Mounjaro in the U.K., so it can meet President Trump's goal of bringing down prices in the U.S.

August 14 at 2:12 PM | wsj.com

Under Pressure from Trump, Eli Lilly (LLY) Raises Price of Diabetes Drug Mounjaro in U.K.

August 14 at 1:59 PM | tipranks.com

Eli Lilly’s Orforglipron Study: A Potential Game-Changer in Obesity Treatment

August 14 at 12:57 PM | tipranks.com

Eli Lilly Completes Phase 3 Study on Orforglipron for Obesity Treatment

August 14 at 12:57 PM | tipranks.com

Eli Lilly accused of bribing doctors to prescribe Mounjaro and other drugs

August 14 at 12:52 PM | msn.com

Lilly signs $1.3 billion deal with Superluminal to discover obesity medicines using AI

August 14 at 12:52 PM | reuters.com

Top Stock Movers Now: Tapestry, Deere, Eli Lilly, and More

August 14 at 12:20 PM | investopedia.com

Eli Lilly hikes price of diabetes drug Mounjaro in UK as Trump pressures pharma to align drug costs

August 14 at 12:10 PM | cnbc.com

Eli Lilly To Raise Mounjaro Price In UK, Expands Obesity Drug Push In India

August 14 at 11:42 AM | benzinga.com

Eli Lilly & Co.: Deep Pullback Near 52‑Week Low Tests Strong Fundamentals And Bullish Analyst Targets

August 14 at 11:15 AM | talkmarkets.com

Eli Lilly (LLY) To Significantly Increase Mounjaro Price in UK

August 14 at 10:06 AM | gurufocus.com

Eli Lilly raises UK price of weight loss drug Mounjaro by up to 170%

August 14 at 8:56 AM | ft.com

Eli Lilly and Company (NYSE:LLY) is Azimuth Capital Investment Management LLC's 4th Largest Position

August 14 at 8:45 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

AVNR, LLY, JNJ, and ABBV Company Descriptions

AbbVie NYSE:ABBV

$204.78 +3.31 (+1.64%)

Closing price 08/14/2025 03:59 PM Eastern

Extended Trading

$204.70 -0.08 (-0.04%)

As of 06:18 AM Eastern

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

(AVNR) NASDAQ:AVNR

AVANIR Pharmaceuticals, Inc. (AVANIR) is a pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of central nervous system disorders. The Company focuses on products for the central nervous system. It also has a number of partnered programs in other therapeutic areas. Its docosanol 10% cream, sold in the United States and Canada as Abreva by its marketing partner GlaxoSmithKline Consumer Healthcare, is the only over-the-counter treatment for cold sores that has been approved by the United Sates Food and Drug Administration (FDA). In October 2010, FDA approved NUEDEXTA, is a combination of dextromethorphan/quinidine, for the treatment of pseudobulbar affect (PBA).

Johnson & Johnson NYSE:JNJ

$174.96 +0.54 (+0.31%)

Closing price 08/14/2025 03:59 PM Eastern

Extended Trading

$175.05 +0.09 (+0.05%)

As of 06:19 AM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Eli Lilly and Company NYSE:LLY

$685.27 +24.78 (+3.75%)

Closing price 08/14/2025 03:59 PM Eastern

Extended Trading

$691.06 +5.79 (+0.84%)

As of 06:19 AM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time